Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Oct 1, 2026 → Dec 1, 2026
See other at-risk trials from University of Alabama at Birmingham

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Primary completion pushed from Oct 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 9 words
    • Site details revised
  2. Primary completion date: Jul 1, 2026 to Oct 1, 2026
    • Study completion date: Sep 1, 2026 to Jul 1, 2027
    v11
  3. Primary completion date: Nov 1, 2025 to Jul 1, 2026
    • Study completion date: Nov 1, 2025 to Sep 1, 2026
    v10
  4. Primary and study completion dates: Mar 3, 2025 to Nov 1, 2025v9
  5. Start date: Aug 25, 2023 to Jan 10, 2024v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary and study completion dates: Dec 31, 2024 to Mar 3, 2025v7
  2. Primary and study completion dates: Apr 1, 2024 to Dec 31, 2024v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 31, 2023 to Aug 25, 2023
    • Site details revised
    v5
  4. Start date: Aug 15, 2023 to Aug 31, 2023v4
  5. Start date: Jul 1, 2023 to Aug 15, 2023v3
  6. Start date: Apr 1, 2023 to Jul 1, 2023v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Trial Details
NCT Number NCT05788016
Lead Sponsor University of Alabama at Birmingham
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions
(from sponsor)		 Arthritis Knee, Arthritis Hip, Chronic Pain
Related terms Chronic Pain
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov